Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment

NCT03868722 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

212

Enrollment

OTHER

Sponsor class

Conditions

CLL

Interventions

DRUG: Acalabrutinib
DRUG: Venetoclax

Sponsor

Rigshospitalet, Denmark

Collaborators

[object Object]
[object Object]
[object Object]